# Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

> **NCT02534935** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 396 (actual)

## Conditions studied

- Meningococcal B Disease

## Interventions

- **BIOLOGICAL:** rLP2086 vaccine
- **BIOLOGICAL:** Pediatric HAV vaccine

## Key facts

- **NCT ID:** NCT02534935
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-31
- **Primary completion:** 2017-08-21
- **Final completion:** 2020-03-17
- **Target enrollment:** 396 (ACTUAL)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02534935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02534935, "Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02534935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*